Efficiency of Liposomal Albendazole for the Treatment of the Patients with Complex Alveolar Echinococcosis: a Comparative Analysis of CEUS, CT, and PET/CT

Overview

Journal Parasitol Res

Specialty Parasitology

Date 2015 Aug 5

PMID 26239800

Citations 8

Authors

Haitao Li

Tao Song

Yongde Qin

Wenya Liu

Xiaohong Li

Yingmei Shao

Hao Wen

Affiliations

Soon will be listed here.

Abstract

We aim to investigate the efficiency of liposomal albendazole (L-ABZ) for the treatment of complex alveolar echinococcosis (CAE) using contrast-enhanced ultrasonography (CEUS), computed tomography (CT), and positron emission tomography (PET)/CT. Twelve patients with CAE admitted to our hospital between June 2000 and June 2011 were included in this retrospective study. CEUS, CT, and PET/CT were used to evaluate the clinical efficiency of L-ABZ for these patients. Effectiveness was defined as significant response after chemotherapy. Effectiveness with clinical significance was defined as complete response after chemotherapy, and non-effectiveness was defined as no response after chemotherapy. Patients were followed up for 3-11 years. Ten patients (83.3%) had a ratio of averaged gray scale in the enhanced band to that of hepatic tissues of ≤1.1, and six patients (50.0%) had a ratio of ≤0.9 as revealed by CEUS. CT scanning results indicated an effective rate of 91.6%. PET/CT indicated a maximal standard uptake (SUVmax) of <2.5 in nine patients (75.0%), which was considered to be effective. A high uptake of fluorodeoxyglucose was observed in three patients (25.0%) with SUVmax ≥2.5, which was considered to be non-effective. Taken together, CEUS, CT, and PET/CT provide objective evaluation of the clinical efficiency of L-ABZ for the treatment of CAE.

Citing Articles

Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.

Liu H, Xie Y, An X, Xu D, Cai S, Chu C Diagnostics (Basel). 2025; 15(5).

PMID: 40075832 PMC: 11898896. DOI: 10.3390/diagnostics15050585.

Chemotherapy for the treatment of alveolar echinococcosis: Where are we?.

Autier B, Robert-Gangneux F, Dion S Parasite. 2024; 31:56.

PMID: 39311470 PMC: 11418394. DOI: 10.1051/parasite/2024055.

LncRNA Regulation Mechanism in Hepatic Alveolar Echinococcosis with Nanosecond Pulse.

Tuergan T, Zhang R, Chen X, Aihemaiti N, Guo X, Ran B Acta Parasitol. 2023; 68(2):420-429.

PMID: 37103765 DOI: 10.1007/s11686-023-00672-3.

Quantitative evaluation of range and metabolic activity of hepatic alveolar echinococcosis lesion microenvironment using PET/CT and multi-site sampling method.

Aini A, Yimingjiang M, Yasen A, Ran B, Jiang T, Li X BMC Infect Dis. 2021; 21(1):702.

PMID: 34301188 PMC: 8299608. DOI: 10.1186/s12879-021-06366-3.

Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography.

Graeter T, Eberhardt N, Shi R, Schmidberger J, Beer A, Beer M Sci Rep. 2020; 10(1):11808.

PMID: 32678174 PMC: 7366930. DOI: 10.1038/s41598-020-68624-9.

References

Said-Ali Z, Grenouillet F, Knapp J, Bresson-Hadni S, Vuitton D, Raoul F . Detecting nested clusters of human alveolar echinococcosis. Parasitology. 2013; 140(13):1693-700. DOI: 10.1017/S0031182013001352. View

Bardonnet K, Vuitton D, Grenouillet F, Mantion G, Delabrousse E, Blagosklonov O . 30-yr course and favorable outcome of alveolar echinococcosis despite multiple metastatic organ involvement in a non-immune suppressed patient. Ann Clin Microbiol Antimicrob. 2013; 12:1. PMC: 3564901. DOI: 10.1186/1476-0711-12-1. View

Azizi A, Blagosklonov O, Lounis A, Berthet L, Vuitton D, Bresson-Hadni S . Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdom Imaging. 2014; 40(1):56-63. DOI: 10.1007/s00261-014-0183-0. View

Reuter S, Nussle K, Kolokythas O, Haug U, Rieber A, Kern P . Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection. 2001; 29(3):119-25. DOI: 10.1007/s15010-001-1081-2. View

Vuitton D . Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus?. Expert Rev Anti Infect Ther. 2009; 7(2):145-9. DOI: 10.1586/14787210.7.2.145. View

Kratzer W, Reuter S, Hirschbuehl K, Ehrhardt A, Mason R, Haenle M . Comparison of contrast-enhanced power Doppler ultrasound (Levovist) and computed tomography in alveolar echinococcosis. Abdom Imaging. 2005; 30(3):286-90. DOI: 10.1007/s00261-004-0263-7. View

Sahin M, Aydin A, Bulbuloglu E, Ciralik H . Experimental hydatid disease of the liver. Eur J Clin Invest. 1997; 27(6):537-8. DOI: 10.1046/j.1365-2362.1997.1530690.x. View

Tao S, Qin Z, Hao W, Yongquan L, Lanhui Y, Lei Y . Usefulness of gray-scale contrast-enhanced ultrasonography (SonoVue®) in diagnosing hepatic alveolar echinococcosis. Ultrasound Med Biol. 2011; 37(7):1024-8. DOI: 10.1016/j.ultrasmedbio.2011.04.014. View

Stumpe K, Renner-Schneiter E, Kuenzle A, Grimm F, Kadry Z, Clavien P . F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy. Infection. 2007; 35(1):11-8. DOI: 10.1007/s15010-007-6133-9. View

10.

Reuter S, Buck A, Manfras B, Kratzer W, Seitz H, Darge K . Structured treatment interruption in patients with alveolar echinococcosis. Hepatology. 2004; 39(2):509-17. DOI: 10.1002/hep.20078. View

11.

Li H, Song T, Shao Y, Tuergan A, Ran B, Wen H . Chemotherapy in alveolar echinococcosis of multi-organs: what's the role?. Parasitol Res. 2013; 112(6):2237-43. DOI: 10.1007/s00436-013-3382-7. View

12.

Dinkel A, Kern S, Brinker A, Oehme R, Vaniscotte A, Giraudoux P . A real-time multiplex-nested PCR system for coprological diagnosis of Echinococcus multilocularis and host species. Parasitol Res. 2011; 109(2):493-8. DOI: 10.1007/s00436-011-2272-0. View

13.

Becce F, Pomoni A, Uldry E, Halkic N, Yan P, Meuli R . Alveolar echinococcosis of the liver: diffusion-weighted MRI findings and potential role in lesion characterisation. Eur J Radiol. 2014; 83(4):625-31. DOI: 10.1016/j.ejrad.2013.12.025. View

14.

Song T, Li H, Yang L, Yao L, Wen H . [Contrast-enhanced ultrasonography of hepatic alveolar echinococcosis in rats: the correaltion of imaging fratures and histologic microvascular density]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2014; 32(3):200-4. View

15.

Li H, Shan J, Shao Y, Tuergan A, Ayifuhan A, Ran B . [Clinical effect and safety of liposomal-albendazole and tablet-albendazole for the treatment of human cystic echinococcosis]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(7):532-6. DOI: 10.3760/cma.j.issn.1007-3418.2011.07.015. View

16.

McManus D, Zhang W, Li J, Bartley P . Echinococcosis. Lancet. 2003; 362(9392):1295-304. DOI: 10.1016/S0140-6736(03)14573-4. View

17.

Ehrhardt A, Reuter S, Buck A, Haenle M, Mason R, Gabelmann A . Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [(18)F] fluorodeoxyglucose positron emission tomography. Abdom Imaging. 2007; 32(6):730-6. DOI: 10.1007/s00261-006-9173-1. View

18.

Crouzet J, Grenouillet F, Delabrousse E, Blagosklonov O, Thevenot T, Di Martino V . Personalized management of patients with inoperable alveolar echinococcosis undergoing treatment with albendazole: usefulness of positron-emission-tomography combined with serological and computed tomography follow-up. Clin Microbiol Infect. 2009; 16(6):788-91. DOI: 10.1111/j.1469-0691.2009.02924.x. View

19.

Eckert J, Thompson R, Michael S, Kumaratilake L . Echinococcus granulosus of camel origin: development in dogs and parasite morphology. Parasitol Res. 1989; 75(7):536-44. DOI: 10.1007/BF00931162. View

20.

Wen H, New R, Muhmut M, Wang J, Wang Y, Zhang J . Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology. 1996; 113 ( Pt 2):111-21. DOI: 10.1017/s003118200006635x. View